Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mathieu Molimard

Showing results (91-100 of 170) with videos related to

Pageof 17
Sort By:
Therapeutic Drug Monitoring|September 22, 2005
Quantification of imatinib in human plasma by high-performance liquid chromatography-tandem mass spectrometryKarine Titier, Stéphane Picard, Dominique Ducint, et al.
Expert Opinion on Drug Safety|April 5, 2014
Cardiovascular events associated with the long-term use of NSAIDs: a review of randomized controlled trials and observational studiesFrancesco Salvo, Stefania Antoniazzi, Mai Duong, et al.
Journal of Hazardous Materials|July 6, 2025
Experimental protocols and models for assessing the permeation of antineoplastic drugs through gloves: From a scoping review to a guidelines proposition for future studiesGuillaume Swierczynski, Joris Guyon, Mathieu Molimard, et al.
Scientific Reports|June 24, 2026
Preliminary pharmacokinetic investigation of two discoidin domain receptor 2 inhibitors in murine plasma and brain using liquid chromatography-tandem mass spectrometry analysisPaul Gueroue, Audrey Burban, Ahmad Sharanek, et al.
Journal of the American Society for Mass Spectrometry|September 9, 2022
A UPLC-MS/MS Method for Plasma Biological Monitoring of Nirmatrelvir and Ritonavir in the Context of SARS-CoV-2 Infection and Application to a CaseJoris Guyon, Marine Novion, Virginie Fulda, et al.
Drug Safety|August 19, 2008
Inhaled corticosteroids and adrenal insufficiency: prevalence and clinical presentationMathieu Molimard, Pierre-Olivier Girodet, Clothilde Pollet, et al.
Clinical Therapeutics|July 22, 2008
Adherence to anti-inflammatory treatment for asthma in clinical practice in FrancePhilippe Latry, Marion Pinet, Anne Labat, et al.
Fundamental & Clinical Pharmacology|August 15, 2009
Medical and non-medical direct costs of chronic low back pain in patients consulting primary care physicians in FranceFanny Depont, Elke Hunsche, Abdelilah Abouelfath, et al.
The European Respiratory Journal|May 26, 2022
Real-life omalizumab exposure and discontinuation in a large nationwide population-based study of paediatric and adult asthma patientsMarc Humbert, Arnaud Bourdin, Camille Taillé, et al.
Clinica Chimica Acta; International Journal of Clinical Chemistry|April 17, 2017
An UPLC-MS/MS method for the quantification of BRAF inhibitors (vemurafenib, dabrafenib) and MEK inhibitors (cobimetinib, trametinib, binimetinib) in human plasma. Application to treated melanoma patientsMarine Rousset, Karine Titier, Stephane Bouchet, et al.
Pageof 17

Showing results (91-100 of 170) with videos related to

Sort By:
Pageof 17
Therapeutic Drug Monitoring|September 22, 2005
Quantification of imatinib in human plasma by high-performance liquid chromatography-tandem mass spectrometryKarine Titier, Stéphane Picard, Dominique Ducint, et al.
Expert Opinion on Drug Safety|April 5, 2014
Cardiovascular events associated with the long-term use of NSAIDs: a review of randomized controlled trials and observational studiesFrancesco Salvo, Stefania Antoniazzi, Mai Duong, et al.
Journal of Hazardous Materials|July 6, 2025
Experimental protocols and models for assessing the permeation of antineoplastic drugs through gloves: From a scoping review to a guidelines proposition for future studiesGuillaume Swierczynski, Joris Guyon, Mathieu Molimard, et al.
Scientific Reports|June 24, 2026
Preliminary pharmacokinetic investigation of two discoidin domain receptor 2 inhibitors in murine plasma and brain using liquid chromatography-tandem mass spectrometry analysisPaul Gueroue, Audrey Burban, Ahmad Sharanek, et al.
Journal of the American Society for Mass Spectrometry|September 9, 2022
A UPLC-MS/MS Method for Plasma Biological Monitoring of Nirmatrelvir and Ritonavir in the Context of SARS-CoV-2 Infection and Application to a CaseJoris Guyon, Marine Novion, Virginie Fulda, et al.
Drug Safety|August 19, 2008
Inhaled corticosteroids and adrenal insufficiency: prevalence and clinical presentationMathieu Molimard, Pierre-Olivier Girodet, Clothilde Pollet, et al.
Clinical Therapeutics|July 22, 2008
Adherence to anti-inflammatory treatment for asthma in clinical practice in FrancePhilippe Latry, Marion Pinet, Anne Labat, et al.
Fundamental & Clinical Pharmacology|August 15, 2009
Medical and non-medical direct costs of chronic low back pain in patients consulting primary care physicians in FranceFanny Depont, Elke Hunsche, Abdelilah Abouelfath, et al.
The European Respiratory Journal|May 26, 2022
Real-life omalizumab exposure and discontinuation in a large nationwide population-based study of paediatric and adult asthma patientsMarc Humbert, Arnaud Bourdin, Camille Taillé, et al.
Clinica Chimica Acta; International Journal of Clinical Chemistry|April 17, 2017
An UPLC-MS/MS method for the quantification of BRAF inhibitors (vemurafenib, dabrafenib) and MEK inhibitors (cobimetinib, trametinib, binimetinib) in human plasma. Application to treated melanoma patientsMarine Rousset, Karine Titier, Stephane Bouchet, et al.
Pageof 17